Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders

    • SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females”
    • Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD
    • Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease
    • Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug approval pathway

    Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued US Patent 11,491,120 by the US Patent and Trademark Office (“USPTO”) ( The patent, titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females”, enables SILO to expand its intellectual property and technology rights for treating rare stress-related medical conditions.

    SPC-15 is a targeted prophylactic ketamine formulation used in a novel protocol to treat and prevent stress-induced affective disorders, including PTSD.

    “After a comprehensive review by USPTO, we are pleased with the scope of the granted claims offering further protection for our novel SPC-15 technology and its market potential for anxiety, PTSD, and related disorders,” said SILO Chief Executive Officer Eric Weisblum.

    SILO collaborates with first-in-class research partners at leading universities to advance research in the medical and psychedelic sectors. The company holds an option to license certain assets currently under development by Columbia University through a commercial evaluation license agreement between both parties. Other drugs in the company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, and SPC-14 as a treatment for Alzheimer’s disease.

    Several therapeutics developed by the company may qualify for the FDA’s streamlined 505(b)(2) regulatory drug approval pathway. Drugs that qualify under the 505(b)(2) pathway may be exempted from conducting repeat studies previously performed on tested drugs, enabling the company to reduce expenses and speed up the time to market ( Other benefits include lower treatment risk due to previous drug approval and the potential to qualify for 3-7 years of market exclusivity.

    Silo Pharma Inc. merges traditional therapeutics with psychedelic research to develop innovative therapeutics for underserved markets, including PTSD, fibromyalgia, Alzheimer’s disease, Parkinson’s disease, rheumatoid arthritis, and other rare neurological conditions. The company collaborates with top universities and research institutions to develop therapeutics that can improve patient outcomes and potentially transform the healthcare industry.

    For more information, visit the company’s website at

    NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at

    About PsychedelicNewsWire

    PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

    To receive instant SMS alerts, text “Groovy” to 844-397-5787 (U.S. Mobile Phones Only)

    For more information please visit

    Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

    Do you have questions or are you interested in working with PNW? Ask our Editor

    PsychedelicNewsWire (PNW)
    San Francisco, California
    415.949.5050 Office

    PsychedelicNewsWire is part of the InvestorBrandNetwork.


    Select A Month

    PsychedelicNewsWire Currently Accepts



    Bitcoin Cash

    Bitcoin Cash

    Doge Coin






    USD Coin

    USD Coin

    Contact us: 415.949.5050